GoAI
Get started
Revvity, Inc. logo

Revvity, Inc.

RVTY

NYSEHealthcareMedical - Diagnostics & Research

Open in GoAI

Previous close

$124.75

+$0.62 · +0.50%

Aug 21, 4:00 PM ET

RVTY company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

65

Undervalued

Momentum

52

Neutral

Sentiment

56

Mixed

Risk resilience

66

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US

Market position

Day range

Current $124.75

52-week range

Current $124.75

Open
$124
Previous close
$124.13
Volume
1.86M
Market cap
13.92B USD
50-day average
$111.18
+12.21% above average
200-day average
$100.58
+24.03% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
13.59B USD
P/E (TTM)
59.4×
P/B (TTM)
1.93×
P/S (TTM)
4.78×
EV / EBITDA
20.51×
Earnings yield
2.20%
Free cash flow yield
4.62%
Dividend yield
0.22%

Profitability & efficiency

Gross margin
52.11%
Operating margin
12.32%
Net margin
8.16%
Return on equity
3.33%
Return on assets
1.99%
Return on invested capital
2.82%

Financial health

Debt / equity
0.46×
Current ratio
1.68×
Altman Z-score
2.89
Piotroski F-score
8 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends66%40%15%-11%Gross margin, FY2021: 59.62%Gross margin, FY2022: 53.16%Gross margin, FY2023: 48.07%Gross margin, FY2024: 48.01%Gross margin, FY2025: 53.08%Operating margin, FY2021: 35.01%Operating margin, FY2022: 23.59%Operating margin, FY2023: 14.52%Operating margin, FY2024: 14.90%Operating margin, FY2025: 12.49%Net margin, FY2021: 24.64%Net margin, FY2022: 17.19%Net margin, FY2023: -4.30%Net margin, FY2024: 10.74%Net margin, FY2025: 8.46%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 59.62%. Gross margin FY2022 53.16%. Gross margin FY2023 48.07%. Gross margin FY2024 48.01%. Gross margin FY2025 53.08%. Operating margin FY2021 35.01%. Operating margin FY2022 23.59%. Operating margin FY2023 14.52%. Operating margin FY2024 14.90%. Operating margin FY2025 12.49%. Net margin FY2021 24.64%. Net margin FY2022 17.19%. Net margin FY2023 -4.30%. Net margin FY2024 10.74%. Net margin FY2025 8.46%.

Income trends

Revenue

2.86B USD+3.67%

Operating income

356.64M USD-13.13%

Net income

241.68M USD-18.31%
Income trends across reported periods4.22B USD2.64B USD1.07B USD−513M USDRevenue, FY2021: 3.83B USDRevenue, FY2022: 3.31B USDRevenue, FY2023: 2.75B USDRevenue, FY2024: 2.76B USDRevenue, FY2025: 2.86B USDOperating income, FY2021: 1.34B USDOperating income, FY2022: 781.12M USDOperating income, FY2023: 399.49M USDOperating income, FY2024: 410.52M USDOperating income, FY2025: 356.64M USDNet income, FY2021: 943.16M USDNet income, FY2022: 569.18M USDNet income, FY2023: −118.38M USDNet income, FY2024: 295.83M USDNet income, FY2025: 241.68M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 3.83B USD. Revenue FY2022 3.31B USD. Revenue FY2023 2.75B USD. Revenue FY2024 2.76B USD. Revenue FY2025 2.86B USD. Operating income FY2021 1.34B USD. Operating income FY2022 781.12M USD. Operating income FY2023 399.49M USD. Operating income FY2024 410.52M USD. Operating income FY2025 356.64M USD. Net income FY2021 943.16M USD. Net income FY2022 569.18M USD. Net income FY2023 −118.38M USD. Net income FY2024 295.83M USD. Net income FY2025 241.68M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.86B USD2.76B USD2.75B USD3.31B USD3.83B USD
Cost of goods sold1.34B USD1.43B USD1.43B USD1.55B USD1.55B USD
Gross profit1.52B USD1.32B USD1.32B USD1.76B USD2.28B USD
Research and development215.84M USD196.84M USD216.58M USD221.62M USD200.34M USD
Selling, general, and administrative945.29M USD715.3M USD706.12M USD757.99M USD741.61M USD
Operating expenses1.16B USD912.14M USD922.7M USD979.61M USD941.95M USD
Interest income31.1M USD73.19M USD72.13M USD3.59M USD2.24M USD
Interest expense92.19M USD96.28M USD98.81M USD103.96M USD102.13M USD
Depreciation and amortization302.26M USD427.85M USD431.77M USD427M USD311.44M USD
Operating income356.64M USD410.52M USD399.49M USD781.12M USD1.34B USD
Net income241.68M USD295.83M USD−118.38M USD569.18M USD943.16M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
11 beats, 0 misses, 0 met estimates
Average EPS surprise
+7.22%
11 comparable reports
Latest EPS result
1.41
Estimate 1.21 · Beat by 16.53%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.771.481.180.89Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 31, 2025: actual 1.42, estimate 1.37, surprise +3.65%, Beat. Q2 2025, reported Apr 28, 2025: actual 1.01, estimate 0.96, surprise +5.21%, Beat. Q3 2025, reported Jul 28, 2025: actual 1.18, estimate 1.14, surprise +3.51%, Beat. Q4 2025, reported Oct 27, 2025: actual 1.18, estimate 1.14, surprise +3.51%, Beat. Q1 2026, reported Feb 2, 2026: actual 1.7, estimate 1.57, surprise +8.28%, Beat. Q2 2026, reported May 5, 2026: actual 1.06, estimate 1.02, surprise +3.92%, Beat. Q3 2026, reported Aug 4, 2026: actual 1.41, estimate 1.21, surprise +16.53%, Beat. Q4 2026, reported Oct 26, 2026: actual —, estimate 1.29, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates802.94M746.59M690.23M633.88MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 31, 2025: actual 729.37M USD, estimate 665.29M USD, surprise +9.63%, Beat. Q2 2025, reported Apr 28, 2025: actual 664.76M USD, estimate 710.82M USD, surprise -6.48%, Miss. Q3 2025, reported Jul 28, 2025: actual 720.28M USD, estimate 699.89M USD, surprise +2.91%, Beat. Q4 2025, reported Oct 27, 2025: actual 698.95M USD, estimate 699.36M USD, surprise -0.06%, Miss. Q1 2026, reported Feb 2, 2026: actual 772.06M USD, estimate 764.94M USD, surprise +0.93%, Beat. Q2 2026, reported May 5, 2026: actual 711.12M USD, estimate 704.07M USD, surprise +1.00%, Beat. Q3 2026, reported Aug 4, 2026: actual 711M USD, estimate 702.96M USD, surprise +1.14%, Beat. Q4 2026, reported Oct 26, 2026: actual —, estimate 694.07M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$110.4

11.50% downside
Past 12 months12-month forecastHigh $125Average $110.4Low $95.00

Rating distribution

29 ratings
Strong buy00%
Buy1552%
Hold1448%
Sell00%
Strong sell00%

Recent analyst actions

12 institutions

RVTY news

gurufocus.com

Revvity Inc (RVTY) Shares Surge 5.0% -- What GF Score of 78 Tells Investors

On August 19, 2026, Revvity Inc (RVTY) shares rose by 5.0% to a current price of $119.45, moving within a 52-week range of $81.22 to $122.11. This upward moveme

Read source
defenseworld.net

Assenagon Asset Management S.A. Has $1.72 Million Stock Position in Revvity Inc. $RVTY

Assenagon Asset Management S.A. lessened its stake in Revvity Inc. (NYSE: RVTY) by 35.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The…

Read source
zacks.com

Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs

RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.

Read source
defenseworld.net

Revvity Inc. $RVTY Shares Acquired by Cetera Investment Advisers

Cetera Investment Advisers raised its position in Revvity Inc. (NYSE: RVTY) by 59.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The…

Read source
businesswire.com

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Wednesday, September 9, 2026 8:45 a.m. ET…

Read source
gurufocus.com

Revvity to Present at Upcoming Investor Conferences

[url="]Revvity, Inc.[/url] (NYSE: RVTY), today announced it will present at the following investor conferences:Wells Fargo 21st Annual Healthcare ConferenceWedn

Read source

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$0.28

2025 complete year0.0% since 2021

2026 partial: $0.21

* Partial calendar year in the available dividend history.

Corporate action history

DividendUpcoming

Ex-dividend Oct 23, 2026

$0.07

Quarterly

Record Oct 23, 2026 · Payment Nov 13, 2026

Dividend

Ex-dividend Jul 17, 2026

$0.07

Quarterly

Record Jul 17, 2026 · Payment Aug 7, 2026

Dividend

Ex-dividend Apr 17, 2026

$0.07

Quarterly

Record Apr 17, 2026 · Payment May 8, 2026

Dividend

Ex-dividend Jan 16, 2026

$0.07

Quarterly

Record Jan 16, 2026 · Payment Feb 6, 2026

Dividend

Ex-dividend Oct 17, 2025

$0.07

Quarterly

Record Oct 17, 2025 · Payment Nov 7, 2025

Dividend

Ex-dividend Jul 18, 2025

$0.07

Quarterly

Record Jul 18, 2025 · Payment Aug 8, 2025

RVTY peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,254.77

+0.83%

Johnson & Johnson logo

JNJ

Johnson & Johnson

$270.24

+1.07%

AbbVie Inc. logo

ABBV

AbbVie Inc.

$265.01

+1.21%

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$152.55

+2.39%

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$390.11

+1.37%

Novartis AG logo

NVS

Novartis AG

$158.86

+1.68%

ETFs holding RVTY

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
400.19M
Weight
0.02%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard S&P 500 ETF logoVanguard S&P 500 ETFVOO
Market value
329.5M
Weight
0.02%
AUM
1.7T USD
Expense ratio
0.03%
Price / 1D
$703.71+0.39%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
288.49M
Weight
0.16%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Value ETF logoVanguard Morningstar Small-Cap Value ETFVBR
Market value
183.28M
Weight
0.27%
AUM
68.3B USD
Expense ratio
0.05%
Price / 1D
$249.18+0.68%
State Street SPDR S&P 500 ETF logoState Street SPDR S&P 500 ETFSPY
Market value
172.28M
Weight
0.02%
AUM
817.87B USD
Expense ratio
0.09%
Price / 1D
$765.72+0.41%
T. Rowe Price Capital Appreciation Equity ETF logoT. Rowe Price Capital Appreciation Equity ETFTCAF
Market value
113.3M
Weight
1.37%
AUM
8.27B USD
Expense ratio
0.31%
Price / 1D
$42.46+0.35%
State Street Health Care Select Sector SPDR ETF logoState Street Health Care Select Sector SPDR ETFXLV
Market value
99.62M
Weight
0.22%
AUM
44.76B USD
Expense ratio
0.08%
Price / 1D
$174.62+1.29%
Dimensional - US Targeted Value ETF logoDimensional - US Targeted Value ETFDFAT
Market value
55.17M
Weight
0.38%
AUM
14.66B USD
Expense ratio
0.28%
Price / 1D
$71.67+0.67%

Continue in GoAI

Research RVTY

research.disclaimer